CardioVere

Looking back at a great meeting this past weekend at . The team enjoyed connecting with the best in heart failure management!

The highlight of the weekend was our clinical study “Non-Contact Molecular Chemical Imaging for Evaluation of Congestion: A Validation Study Compared to MRI” being presented by Dr. Peter Eckman of the Minneapolis Heart Institute Foundation. Thank you to Dr. Eckman and the rest of the CardioVere Team for an insightful presentation! Visit our website to have a look at the study poster: https://bit.ly/3SFuvKJ

According to the CDC, 1 in 5 Americans will develop Heart Failure (HF) in their lifetime. Today on , we bring awareness to Cardiovascular Disease (CVD) and the need for better heart failure management. At CardioVere, it is our mission to provide clinicians with precise information earlier to improve HF patient care.

How? We’re working to advance the standard of care with breakthrough, patented Molecular Chemical Imaging (MCI) technology that can empower providers and HF patients to screen, manage, and monitor the disease at all points-of-care. CardioVere has the potential to help detect HF earlier, reduce readmissions, and improve patient outcomes.

Learn more about CardioVere technology now at https://bit.ly/3DWryB4

CardioVere is proud to celebrate World Patient Safety Day 2022! With our breakthrough solution intended to precisely and objectively measure tissue congestion in heart failure patients, CardioVere has the potential to provide physicians with more accurate data, advancing the standard of care for heart failure patients.

Established by the World Health Organization (WHO), World Patient Safety Day gives us the opportunity to recognize the importance of patient safety and discover new ways to care for patients. Visit our website to learn more about our technology and how it could contribute to a safer patient experience. Visit: https://bit.ly/3ROg4n3

According to Heart Failure Society of America - HFSA, the prevalence of heart failure is expected to increase from 6.5 million Americans to >8 million by 2030. CardioVere is designed to be the next generation congestion measurement device to help manage heart failure patients using our patented Molecular Chemical Imaging (MCI) technology.

Join us at where we will unveil our latest clinical study results comparing our CardioVere technology to the traditional MRI method. We look forward to being among the best of heart failure science, research, and practical management and hope you can join us for our poster presentation.

American Heart month is underway and today we celebrate Go Red For Women National Wear Red Day®, designed to increase women’s heart health awareness. About 435,000 women have heart attacks in the U.S. yearly. Symptoms can be so mild they’re dismissed as something minor. Learn the important warning signs: https://bit.ly/32Wt71E. ChemImage Corporation understands the impact of cardiac health and is leveraging our patented technology to develop advancements in precision medicine, learn more: https://bit.ly/3rsehtq

Warning Signs and Symptoms Learn more about the warning signs of heart attack and stroke in women that may differ from those men experience.

We are excited to welcome Carl Denys to the ChemImage team! As a seasoned executive who thrives on leading teams and promoting customer-focused cultures, Carl joins us as Vice President, Medical Devices. He will focus on identifying expansion opportunities for the company’s patented technology in medical applications. To read the full press release, click here: https://bit.ly/31nnZ5t

Carl Denys Joins ChemImage as Vice President, Medical Devices | ChemImage Corporation Advanced Imaging and Machine Learning Company Taps Medical Device Executive to Lead Expansion in Medical Applications for Patented Technology ChemImage, a leader in advanced imaging and machine learning technology, has recruited Carl Denys to its executive management team. Mr. Denys will report to P...

Did you know that more than 6 million Americans are living with heart failure? ChemImage Corporation is developing ways to help heart failure patients and assist clinicians in assessment and monitoring with the use of CardioVere. Check out our latest blog post, “Advances in Home Monitoring of Heart Failure Patients.” https://bit.ly/3wAIes1 American Heart Association SPIE, the international society for optics and photonics

Advances in Home Monitoring of Heart Failure Patients ChemImage is also exploring and developing ways to help heart failure patients and assist clinicians in assessment and monitoring by developing a non-invasive early indicator of acute HF decompensation called CardioVere.